A computer-assisted workflow helps pharmacists deprescribe medications that patients no longer need after leaving the ICU, researchers reported in the Journal of the American College of Clinical Pharmacy.
specialtypharmacycontinuum.com/a/ch8BAA/t

The FDA approved an updated label with additional data reinforcing the safety and efficacy profile of Biktarvy for use during pregnancy.
specialtypharmacycontinuum.com/a/nB8BAA/t

With databases chock-full of patient financial and health information, pharmacies can be “a treasure trove” for criminals and hackers looking to profit.
specialtypharmacycontinuum.com/a/cx8BAA/t

Pharmacy benefit managers can audit pharmacies in their networks at any time, so it is crucial to have a fee key audit survival tools on hand, experts said at the 2024 MHA Business Summit
specialtypharmacycontinuum.com/a/ex8BAA/t

Pharmacy leaders can contract with drug manufacturers to deliver enhanced services like adverse event monitoring & patient educational materials. A few strategies can ensure a successful partnership, according to a session at the 2024 MHA Business Summit specialtypharmacycontinuum.com/Online-First/A…

The FDA approved Lutathera for pediatric patients aged 12 years and older with SSTR-positive gastroenteropancreatic neuroendocrine tumors, including foregut, midgut and hindgut neuroendocrine tumors. 
specialtypharmacycontinuum.com/a/WR8BAA/t

The FDA approved nogapendekin Anktiva with Bacillus Calmette-Guérin for adult patients with BCG-unresponsive non–muscle-invasive bladder cancer with carcinoma in situ with or without papillary tumors.
specialtypharmacycontinuum.com/a/Vx8BAA/t

The FDA granted accelerated approval to Ojemda for patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion or rearrangement, or BRAF V600 mutation.
specialtypharmacycontinuum.com/a/VR8BAA/t

In a post-COVID world, pharmacies are confronting several convergent challenges: drug scarcity, new regulation, tight budgets and staff shortages. A Bluesight report outlines how pharmacies are meeting these various challenges.
specialtypharmacycontinuum.com/a/Sx8BAA/t

The FDA approved Alecensa for adjuvant treatment following tumor resection in patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, as detected by an FDA-approved test.
specialtypharmacycontinuum.com/a/OR8BAA/t

The FDA approved a new indication for the subcutaneous administration of Entyvio  for maintenance therapy in adults with moderate to severe active Crohn’s disease after induction therapy with IV vedolizumab. 
specialtypharmacycontinuum.com/a/RR8BAA/t

CMS has released the final part 1 guidance for the new Medicare Prescription Payment Plan, part of President Joe Biden’s changes to prescription drug pricing law. 
specialtypharmacycontinuum.com/a/Mh8BAA/t

Cardinal Health has released its 2024 Biosimilars Report outlining the ways in which consumers and pharmacies can benefit from the newly approved biosimilars to AbbVie’s Humira.
specialtypharmacycontinuum.com/a/Hx8BAA/t

The convenience and accessibility offered by telepharmacy increased patient access to clinical pharmacy services at one Midwest health system following the COVID-19 pandemic.
specialtypharmacycontinuum.com/a/HR8BAA/t

The Emergency Care Research Institute has released its annual report detailing top safety concerns for patients, which range from drug shortages to the COVID-19 pandemic’s lingering effects on novice clinicians.
specialtypharmacycontinuum.com/a/Gx8BAA/t

In the last 15 years, cell and gene therapies have emerged as transformative treatments for diseases that previously had no approved therapy options.
specialtypharmacycontinuum.com/a/6h4BAA/t

The number of active, ongoing drug shortages has reached 323, the highest tally ASHP has recorded since it began tracking this data with the University of Utah Drug Information Service in 2001, according to a new report. 
specialtypharmacycontinuum.com/a/-R4BAA/t

The number of active, ongoing drug shortages has reached 323, the highest tally the American Society of Health-System Pharmacists has recorded since it began tracking this data with the University of Utah Drug Information Service in 2001.
specialtypharmacycontinuum.com/a/-R4BAA/t

Last November, FDA warned pharmaceutical companies that more than 100 patents were improperly or inaccurately listed on the Orange Book. On Jan.18, Sen. Amy Klobuchar (D-Minn.) sent letters to 6 pharmaceutical companies that had failed to act.
specialtypharmacycontinuum.com/a/8x4BAA/t